论文部分内容阅读
目的:探讨耐药蛋白GST-π和LRP与TopoⅡ在三阴性乳腺癌组织中的表达及其临床意义。方法:选取术前未行化疗和内分泌治疗的乳腺癌标本252例,利用免疫组织化学方法对ER、PR和HER-2蛋白表达进行检测,根据结果将其分为三阴性乳腺癌和非三阴性乳腺癌,分别检测耐药蛋白GST-π、LRP与TopoⅡ在两组内的表达水平。结果:18.7%(47/252)的病例为三阴性乳腺癌,其耐药蛋白GST-π的表达水平明显高于非三阴性乳腺癌(χ2=10.466,P=0.001),而LRP与TopoⅡ的表达水平在两组之间差异无统计学意义,P值分别为0.678和0.777。结论:与乳腺癌其他亚型相比,三阴性乳腺癌具有更强的耐药性,而药蛋白GST-π高表达可能是其耐药的重要因素之一。
Objective: To investigate the expression of GST-π, LRP and TopoⅡ in triple negative breast cancer and its clinical significance. Methods: 252 cases of breast cancer without chemotherapy and endocrine therapy were selected. The expression of ER, PR and HER-2 protein were detected by immunohistochemistry. According to the results, they were divided into triple negative breast cancer and non-triple negative Breast cancer were detected in the resistance protein GST-π, LRP and Topo Ⅱ expression levels in both groups. Results: In 18.7% (47/252) cases of triple negative breast cancer, the expression of GST-π was significantly higher than that in non-triple negative breast cancer (χ2 = 10.466, P = 0.001) There was no significant difference in the expression level between the two groups, with P values of 0.678 and 0.777, respectively. Conclusion: Compared with other subtypes of breast cancer, triple negative breast cancer is more resistant, and high expression of GST-π protein may be one of the important factors of its resistance.